Consistent with this, our results showed that the PLK1 inhibitors volasertib and BI-2536 effectively suppressed STAT3 phosphorylation, alongside AKT and ERK phosphorylation, and reduced c-Myc expression across all EGFR-mutant NSCLC cell lines, including those with acquired resistance mutations (Fig. 3F). This evidence concerns the gene PLK1 and non-small cell lung carcinoma.